Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background/Aims</h3><p>Genetic alterations in intrahepatic cholangiocarcinoma (iCCA) are increasingly well‐characterized, but their impact on outcome and prognosis remain unknown.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Approach/Results</h3><p>This bi‐institutional study of patients with confirmed iCCA (n=412) used targeted next‐generation sequencing of primary tumors to define associations among genetic alterations, clinicopathological variables, and outcome. The most common oncogenic alterations were <i>IDH1</i> (20%), <i>ARID1A</i> (20%), <i>TP53</i> (17%), <i>CDKN2A</i> (15%), <i>BAP1</i> (15%), <i>FGFR2</i> (15%), <i>PBRM1</i> (12%), and <i>KRAS</i> (10%). <i>IDH1/2</i> mutations (<i>mut</i>) were mutually exclusive with <i>FGFR2</i> fusions (<i>fus</i>), but neither was associated with outcome. For all patients, <i>TP53</i> (p<0.0001), <i>KRAS</i> (p=0.0001), and <i>CDKN2A</i> (p<0.0001) alterations predicted worse overall survival (OS). These high‐risk alterations were enriched in advanced disease but adversely impacted survival across all stages, even when controlling for known correlates of outcome (multifocal disease, lymph node involvement, bile duct type, periductal infiltration). In resected patients (n=209), <i>TP53mut</i> (HR=1.82, 95%CI=1.08‐3.06, p=0.03) and <i>CDKN2A</i> deletions (<i>del</i>) (HR=3.40, 95%CI=1.95‐5.94, p<0.001) independently predicted shorter OS, as did high‐risk clinical variables (multifocal liver disease [p<0.001]; regional lymph node metastases [p<0.001]), whereas <i>KRASmut</i> (HR=1.69, 95%CI=0.97‐2.93, p=0.06) trended toward statistical significance. The presence of both or neither high‐risk clinical or genetic factors represented outcome extremes (median OS=18.3 vs. 74.2 months, p<0.001), with high‐risk genetic alterations alone (median OS=38.6 months, 95%CI=28.8‐73.5) or high‐risk clinical variables alone (median OS=37.0 months, 95%CI=27.6‐NA) associated with intermediate outcome. <i>TP53mut, KRASmut,</i> and <i>CDKN2Adel</i> similarly predicted worse outcome in patients with unresectable iCCA. <i>CDKN2Adel</i> tumors with high‐risk clinical features were notable for limited survival and no benefit of resection over chemotherapy. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p><i>TP53</i>, <i>KRAS,</i> and <i>CDKN2A</i> alterations were independent prognostic factors in iCCA when controlling for clinical and pathologic variables, disease stage, and treatment. Since genetic profiling can be integrated into pre‐treatment therapeutic decision‐making, combining clinical variables with targeted tumor sequencing may identify patient subgroups with poor outcome irrespective of treatment strategy. </p></section>

A Novel Approach to Quantify Heterogeneity of Intrahepatic Cholangiocarcinoma: the Hidden-Genome Classifier

Identification of Molecular Subtypes for Integrated Multi-Omics Analysis for Use in Guiding Precision Medicine in Hepatocellular Carcinoma.

Identification of two heterogeneous subtypes of hepatocellular carcinoma with distinct pathway activities and clinical outcomes based on gene set variation analysis

Integrated Multi-Omic Analysis To Reveal Comprehensive Tumor Heterogeneity And Novel Immunophenotypic Classification In Primary Liver Cancer.

Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma

Understanding the heterogeneity in liver hepatocellular carcinoma with a special focus on malignant cell through single-cell analysis

Cell Culture System for Analysis of Genetic Heterogeneity Within Hepatocellular Carcinomas and Response to Pharmacologic Agents.

Machine learning developed an intratumor heterogeneity signature for predicting prognosis and immunotherapy benefits in cholangiocarcinoma

Intratumoral heterogeneity and clonal evolution in liver cancer

Exploring the Genomic Landscape of Hepatobiliary Cancers to Establish a Novel Molecular Classification System

Multiomic Analysis Reveals Comprehensive Tumor Heterogeneity and Distinct Immune Subtypes in Multifocal Intrahepatic Cholangiocarcinoma

Integrated Multiomic Analysis Reveals Comprehensive Tumour Heterogeneity and Novel Immunophenotypic Classification in Hepatocellular Carcinomas

Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma

Multimodule characterization of immune subgroups in intrahepatic cholangiocarcinoma reveals distinct therapeutic vulnerabilities

IDH Mutation Subgroup Status Associates with Intratumor Heterogeneity and the Tumor Microenvironment in Intrahepatic Cholangiocarcinoma

Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma

Deep learning-based phenotyping reclassifies combined hepatocellular-cholangiocarcinoma

Concordance in Oncogenic Alterations Between the Primary Tumor and Advanced Disease: Insights Into the Heterogeneity of Intrahepatic Cholangiocarcinoma

Whole-exome Mutational and Transcriptional Landscapes of Combined Hepatocellular Cholangiocarcinoma and Intrahepatic Cholangiocarcinoma Reveal Molecular Diversity

Identifying gastric cancer molecular subtypes by integrating DNA-based hierarchical classification strategy and clinical stratification